336 related articles for article (PubMed ID: 12800807)
1. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
[TBL] [Abstract][Full Text] [Related]
3. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
5. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
6. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
Sun H; Ette EI; Ludden TM
J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
[TBL] [Abstract][Full Text] [Related]
7. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
Lu J; Gries JM; Verotta D; Sheiner LB
J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):343-62. PubMed ID: 11677931
[TBL] [Abstract][Full Text] [Related]
8. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
[TBL] [Abstract][Full Text] [Related]
12. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
Yang S; Roger J
Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
[TBL] [Abstract][Full Text] [Related]
13. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
Knights J; Rohatagi S
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
[TBL] [Abstract][Full Text] [Related]
14. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
[TBL] [Abstract][Full Text] [Related]
17. Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.
Krauss M; Tappe K; Schuppert A; Kuepfer L; Goerlitz L
PLoS One; 2015; 10(10):e0139423. PubMed ID: 26431198
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
[TBL] [Abstract][Full Text] [Related]
20. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
Periclou AP; Avramis VI
Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
